Fennec Pharmaceuticals Inc. (TSX: FRX)
FRX trades on the Toronto Stock Exchange in Life Sciences, headquartered in North Carolina, United States. Numbers below come from the TMX issuer list, Yahoo Finance closes and the Bank of Canada rate, each with its source.
Issuer list, sector and C$ market cap: TMX Group TSX and TSXV listed companies, as of September 30, 2026. US$ figures convert C$ at 1.4263 C$ per US$, the Bank of Canada daily rate for October 14, 2026. Close and returns: Yahoo Finance daily closes for FRX.TO, last bar 2026-10-14, computed by Sophia Capital.
Profile
| Field | Value |
|---|---|
| Ticker | FRX on the Toronto Stock Exchange |
| Yahoo symbol | FRX.TO |
| Sector | Life Sciences |
| Headquarters | North Carolina, United States |
| Listed | 2001-06-04 |
| Listing type | IPO |
| Shares outstanding | 35,138,487 |
| Also listed on | NasdaqCM |
| Index membership | Not in an S&P/TSX index per the TMX list |
| SEC CIK | 0001211583 |
| Website | No company website on record |
| US listing | FENC |
Returns
| Window | Return |
|---|---|
| 1 day | -0.1% |
| 1 week | -1.9% |
| 1 month | -15.4% |
| 3 months | -2.2% |
| 6 months | +66.9% |
| Year to date | +36.5% |
| 1 year | +17.6% |
| From 52-week high | -17.9% |
| 52-week range | C$8.10 to C$17.63 |
Links
SEDAR+ is linked for searching only; nothing on this page is taken from it.
Recent Canadian filings by type
291 documents in 9 types. Each title links to the document at its source.
News release (29)
| Document | Type | Filed |
|---|---|---|
| Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK® in… | News release (8-K) | 2026-09-17 |
| Press Release for Quarter June 30, 2026 (furnished herewith). Period 2026-06-30 | News release (10-Q) | 2026-08-13 |
| FENNEC PHARMACEUTICALS ANNOUNCES NEW RESEARCH supporting INTEGRATION AND use of pedmark® at the 2026 ASCO Annual Meeting | News release (8-K) | 2026-05-22 |
| Press Release dated May 18, 2026 | News release (8-K) | 2026-05-18 |
Management information circular / proxy (2)
| Document | Type | Filed |
|---|---|---|
| DEF 14A | Proxy statement (DEF 14A) | 2026-04-28 |
| DEF 14A | Proxy statement (DEF 14A) | 2025-04-25 |
Prospectus (3)
| Document | Type | Filed |
|---|---|---|
| 424B5 | Prospectus supplement (424B5) | 2025-11-18 |
| 424B5 | Prospectus supplement (424B5) | 2025-11-17 |
| 424B5 | Prospectus supplement (424B5) | 2025-11-13 |
Annual report (2)
| Document | Type | Filed |
|---|---|---|
| 10-K Period 2025-12-31 | Annual report (10-K) (10-K) | 2026-03-27 |
| 10-K Period 2024-12-31 | Annual report (10-K) (10-K) | 2025-03-26 |
Quarterly report (6)
| Document | Type | Filed |
|---|---|---|
| 10-Q Period 2026-06-30 | Quarterly report (10-Q) (10-Q) | 2026-08-13 |
| 10-Q Period 2026-03-31 | Quarterly report (10-Q) (10-Q) | 2026-05-14 |
| 10-Q Period 2025-09-30 | Quarterly report (10-Q) (10-Q) | 2025-11-13 |
| 10-Q Period 2025-06-30 | Quarterly report (10-Q) (10-Q) | 2025-08-14 |
Early warning / ownership (14)
| Document | Type | Filed |
|---|---|---|
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-08-14 |
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-08-14 |
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-08-13 |
| Schedule 13G amendment | Schedule 13G (SCHEDULE 13G/A) | 2026-05-15 |
Insider report (176)
| Document | Type | Filed |
|---|---|---|
| Form 3 | Form 3 (3) | 2024-11-04 |
| Form 3 | Form 3 (3) | 2024-11-04 |
| Form 3 | Form 3 (3) | 2024-11-04 |
| Form 4 | Form 4 (4) | 2026-10-13 |
Certification (24)
| Document | Type | Filed |
|---|---|---|
| EX-31.1 Period 2026-06-30 | Certification (SOX 302/906) (10-Q) | 2026-08-13 |
| EX-31.2 Period 2026-06-30 | Certification (SOX 302/906) (10-Q) | 2026-08-13 |
| EX-32.1 Period 2026-06-30 | Certification (SOX 302/906) (10-Q) | 2026-08-13 |
| EX-31.1 Period 2026-03-31 | Certification (SOX 302/906) (10-Q) | 2026-05-14 |
Other (35)
| Document | Type | Filed |
|---|---|---|
| 8-K | Current report (8-K) (8-K) | 2026-09-17 |
| FORM 8-K | Current report (8-K) (8-K) | 2026-06-10 |
| 8-K | Current report (8-K) (8-K) | 2026-05-22 |
| 8-K | Current report (8-K) (8-K) | 2026-05-18 |
Sources: SEC EDGAR filings (public records). Documents filed only on SEDAR+ are not copied here; search SEDAR+ for the full record.
Trading halts
No CIRO halt notices for this company in our data.
Source: Canadian Investment Regulatory Organization (CIRO), Halts/Resumptions newsroom, notices since 2024-10-15.
Upcoming events
No upcoming earnings date, call or meeting announced in the SEC filings and newswire releases we read.
Source: dates read from the company's SEC filings and newswire releases; each row links to the announcement.
US private placements (SEC Form D)
| Filed | Securities | Sold | Offered | Filing |
|---|---|---|---|---|
| 2017-06-08 | Equity | US$7.6M | US$7.6M | SEC EDGAR |
| 2014-12-15 | Equity | US$2.2M | US$2.2M | SEC EDGAR |
| 2013-11-27 | Equity | US$1.6M | US$1.6M | SEC EDGAR |
Source: SEC EDGAR Form D filings matched on SEC CIK. Amounts are US$ as filed.
Peers in Life Sciences
| Ticker | Company | Exchange | Market cap (C$) | 1 month | 1 year |
|---|---|---|---|---|---|
| WEED | Canopy Growth Corporation | TSX | C$537.4M | -22.0% | -46.4% |
| ACB | Aurora Cannabis Inc. | TSX | C$365.4M | +11.9% | -20.0% |
| EPRX | Eupraxia Pharmaceuticals Inc. | TSX | C$844.6M | -16.5% | +11.4% |
| CPH | Cipher Pharmaceuticals Inc. | TSX | C$346.0M | -9.6% | -6.3% |
| EDT | Spectral Medical Inc. | TSX | C$335.9M | -14.0% | -20.7% |
The app has the price chart, every filing, private raises and the full peer set for FRX.
Open in the app